Status:
UNKNOWN
Renin Angiotensin System - CoronaVirus
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
COVID 19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the study is to demonstrate overactivation of Renin Angiotensine System (RAS) in positives COVID-19 patient, especially in those with the most serious clinical forms where the mortality of ...
Eligibility Criteria
Inclusion
- Positive COVID 19 patients hospitalized in conventionnal hospitalisation
- Patients hospitalized in intensive care secondary to COVID-19 : Patient under invasive mechanical ventilation (PaO2 / FiO2 ratio \<300; PEEP\> = 5 cmH20; PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample; PaO2 / FiO2 ratio\> 300)
Exclusion
- Minor patient
- Patient deprived of liberty
- Patient's refusal to participate in the study
- Patient for whom therapeutic limitation measures such as non-admission to intensive care have been issued
Key Trial Info
Start Date :
April 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04337008
Start Date
April 3 2020
End Date
July 31 2020
Last Update
April 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE
Marseille, France, 13005